Genetic risk scores of disease and mortality capture differences in longevity, economic behavior, and insurance outcomes

Richard Karlsson Linner; Philipp D Koellinger

doi:10.1101/2020.03.30.20047290

Abstract

Widespread genetic testing for diseases may cause adverse selection, escalating premiums, or discrimination in various insurance markets. Here, without systematically informing study participants of their genetic predisposition, we estimate to what extent genetic data are informative about differences in longevity, health expectations, and economic behavior. We compute measures of genetic liability (polygenic scores) for 27 common diseases and mortality risks in 9,272 participants of the Health and Retirement Study (HRS). Survival analysis suggests that the highest decile of cumulative genetic risk can distinguish a median lifespan up to 4.5 years shorter, a difference that is similar to or larger than that distinguished by conventional actuarial risk factors, including sex. Furthermore, greater genetic liability is associated with less long-term care insurance, among other economic behaviors. We conclude that the rapid developments in genetic epidemiology pose new challenges for regulating consumer genetics and insurance markets, requiring urgent attention from policymakers.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

We gratefully acknowledge Netspar for financially supporting this research project with a topicality grant (BD2018.01). This work was carried out on the Dutch national e-infrastructure (grant 17148) with support of the SURF Cooperative. Philipp Koellinger was financially supported by an ERC Consolidator Grant (647648 EdGe). HRS is supported by the National Institute on Aging (NIA U01AG009740). The genotyping was funded separately by the National Institute on Aging (RC2 AG036495, RC4 AG039029). Neither the authors nor their institutions received payment from a third party that influenced the independence of any aspect of the submitted work.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes